162 related articles for article (PubMed ID: 31842658)
21. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
[TBL] [Abstract][Full Text] [Related]
22. Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.
Vitzthum LK; Straka C; Sarkar RR; McKay R; Randall JM; Sandhu A; Murphy JD; Rose BS
J Natl Compr Canc Netw; 2019 Dec; 17(12):1497-1504. PubMed ID: 31805534
[TBL] [Abstract][Full Text] [Related]
23. Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden.
Lin E; Garmo H; Hagström E; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
Br J Cancer; 2023 Mar; 128(5):814-824. PubMed ID: 36522475
[TBL] [Abstract][Full Text] [Related]
24. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
25. Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer.
George G; Rudman S; Fleure L; Moon Z; Garmo H; Cahill F; Fox L; Moss C; Wylie H; Haire A; Van Hemelrijck M
Semin Oncol Nurs; 2022 Aug; 38(4):151236. PubMed ID: 34920915
[TBL] [Abstract][Full Text] [Related]
26. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
[TBL] [Abstract][Full Text] [Related]
27. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
28. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
Kuo YF; Goodwin JS; Shahinian VB
BMC Health Serv Res; 2008 Jul; 8():146. PubMed ID: 18620606
[TBL] [Abstract][Full Text] [Related]
30. Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden.
Bill-Axelson A; Garmo H; Lambe M; Bratt O; Adolfsson J; Nyberg U; Steineck G; Stattin P
Eur Urol; 2010 Mar; 57(3):390-5. PubMed ID: 19914773
[TBL] [Abstract][Full Text] [Related]
31. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.
Van Hemelrijck M; Wigertz A; Sandin F; Garmo H; Hellström K; Fransson P; Widmark A; Lambe M; Adolfsson J; Varenhorst E; Johansson JE; Stattin P;
Int J Epidemiol; 2013 Aug; 42(4):956-67. PubMed ID: 22561842
[TBL] [Abstract][Full Text] [Related]
32. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B
Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
[TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
34. Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer.
Chung SD; Liu SP; Lin HC; Wang LH
PLoS One; 2014; 9(6):e101254. PubMed ID: 24971988
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
[TBL] [Abstract][Full Text] [Related]
36. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
[TBL] [Abstract][Full Text] [Related]
37. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
[TBL] [Abstract][Full Text] [Related]
38. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
[TBL] [Abstract][Full Text] [Related]
40. Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group.
Sandblom G; Dufmats M; Nordenskjöld K; Varenhorst E
Cancer; 2000 Mar; 88(6):1445-53. PubMed ID: 10717629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
